Warn Patients Not to Rely on OTC Primatene Mist for Asthma

January 2019

Primatene Mist (epinephrine) will return to OTC shelves for relieving mild symptoms of intermittent asthma in patients age 12 and up.

It was withdrawn in 2011 due to chlorofluorocarbon (CFC) propellant regulations, NOT safety issues. But most of us were happy to see it go.

Now Primatene Mist is back with an HFA propellant.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cardiology Be Prepared With Answers About the New Cholesterol Guidelines
Asthma Warn Patients Not to Rely on OTC Primatene Mist for Asthma
Antihypertensives Ease Concerns About Cancer Risk With BP Meds
Diabetes Compare Cardiovascular Benefits of SGLT2 Inhibitors for Type 2 Diabetes
MRSA Don't Consider MRSA Decolonization for Most Outpatients
Dyslipidemia Don't Be Too Quick to Jump on the Vascepa (Icosapent Ethyl) Bandwagon
Oral Health Reset Perceptions About Treating Dental Pain
Antibiotics Save the New Tetracycline Nuzyra as a Last Resort
Antiarrhythmics Take Notice When Patients Are on Amiodarone
Venous Thromboembolism Guide Appropriate VTE Prophylaxis After Surgery or Hospitalization
Supplements Be Ready for Patients to Ask About Eye Supplements for Blue Light
Iron Consider Expanding Use of Intravenous Iron
Liver Disease Take Special Precautions When Patients With Cirrhosis Undergo Surgery